Amicus Therapeutics, a biopharmaceutical company developing drugs for rare and orphan diseases, has appointed two new senior members of the commercial and executive team. Mark Baldry, a biopharmaceutical brand strategist with senior- level experience at Biogen Inc. and Shire plc, has joined the company as vice president of global marketing. Willem van Weperen, most recently the former chief commercial officer of Prosensa Holding N.V., has been appointed regional Vice president and country manager, International. Both Mr. Baldry and Mr. van Weperen held the positions of global head of marketing for rare diseases at Shire and Genzyme, respectively. Additionally, Hung Do, Ph.D. has been promoted to chief science officer.
Mr. Baldry has more than 25 years experience in the life science industry and joins Amicus from Biogen Inc., where he most recently served as vice president, public affairs and previously as vice president, new product commercialization. Prior to Biogen, Mr. Baldry held roles of increasing responsibility at Shire plc, including head of marketing, market access, and public affairs, Europe, Middle East and Africa (EMEA) for the Human Genetic Therapies division. Mr. Baldry will be responsible for building and managing the global marketing team and brand strategy for Galafold (migalastat) for Fabry disease, as well as future products commercialized by Amicus.
Mr. van Weperen has more than 20 years of experience and most recently served as chief commercial officer of Prosensa Holding N.V. (acquired by BioMarin). Previously, he was head of global marketing in the rare genetic disease business unit at Genzyme and General Manager of Genzyme Netherlands. Mr. van Weperen will be responsible for managing the commercial launch of Galafold for Fabry disease in the Netherlands, Belgium and several Central & Eastern European countries, as well as the Middle East, Africa, Asia Pacific and Latin America.
Source: Amicus Therapeutics